scholarly journals MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis

2016 ◽  
Vol 19 (1) ◽  
pp. 118-127 ◽  
Author(s):  
Praneil Patel ◽  
Hediyeh Baradaran ◽  
Diana Delgado ◽  
Gulce Askin ◽  
Paul Christos ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
High Grade ◽  
Mr Perfusion ◽  
Perfusion Weighted Imaging ◽  
High Grade Gliomas

scholarly journals Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis

2017 ◽  
Vol 28 (3) ◽  
pp. 401-411 ◽  
Author(s):  
Abdul W. Abbasi ◽  
Henriette E. Westerlaan ◽  
Gea A. Holtman ◽  
Kamal M. Aden ◽  
Peter Jan van Laar ◽  
...  
Keyword(s):  
Systematic Review ◽  
Tumour Progression ◽  
Meta Analysis ◽  
High Grade ◽  
High Grade Gliomas

Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis

2017 ◽  
Vol 42 (2) ◽  
pp. 263-275 ◽  
Author(s):  
Davide Tiziano Di Carlo ◽  
Federico Cagnazzo ◽  
Nicola Benedetto ◽  
Riccardo Morganti ◽  
Paolo Perrini
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
High Grade ◽  
High Grade Gliomas

scholarly journals The Value of Diffusion Tensor Imaging in Differentiating High-Grade Gliomas from Brain Metastases: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e112550 ◽  
Author(s):  
Rui Jiang ◽  
Fei-Zhou Du ◽  
Ci He ◽  
Ming Gu ◽  
Zhen-Wu Ke ◽  
...  
Keyword(s):  
Systematic Review ◽  
Diffusion Tensor Imaging ◽  
Brain Metastases ◽  
Diffusion Tensor ◽  
Meta Analysis ◽  
High Grade ◽  
High Grade Gliomas

scholarly journals Discriminators of Pseudoprogression and True Progression in High-Grade Gliomas: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Christopher Stephen Taylor ◽  
Justyna O. Ekert ◽  
Viktoria Sefcikova ◽  
Naomi Fersht ◽  
George Samandouras
Keyword(s):  
Systematic Review ◽  
Sensitivity And Specificity ◽  
Tumour Progression ◽  
Meta Analysis ◽  
Amide Proton ◽  
Forest Plot ◽  
High Grade ◽  
Recurrence Rates ◽  
Management Options ◽  
High Grade Gliomas

Abstract BackgroundHigh-grade gliomas remain the most common primary brain tumour with limited treatments options and early recurrence rates following adjuvant treatments. However, differentiating true tumour progression (TTP) from treatment-related effects or pseudoprogression (PsP), may critically influence subsequent management options. Structural MRI is routinely employed to evaluate treatment responses, but misdiagnosis of TTP or PsP may lead to continuation of ineffective or premature cessation of effective treatments, respectively. MethodsA systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) method. The entirety of the Embase and MEDLINE databases were searched for methods differentiating PsP and TTP, and studies were selected using pre-specified eligibility criteria. The sensitivity and specificity of included studies were summarised in a forest plot. Three of the identified methods were assessed in a separate subgroup meta-analysis.ResultsTwenty-six studies assessing seven distinct neuroimaging methods in 1145 patients were included in the systematic review. 18F-fluoroethyltyrosine PET (FET PET) and amide proton transfer-weighted MRI (APTw-MRI) showed high diagnostic accuracy, but results were based on single low-powered studies. The highest performing methods in the subgroup analysis were DWI (AUC = 0.95 [0.92 – 0.96]) and DSC-pMRI (AUC = 0.94 [0.91 – 0.95]), compared to DCE-pMRI (AUC = 0.90 [0.87 – 0.93]).ConclusionsBoth DWI and DSC-pMRI performed with high sensitivity and specificity for differentiating PsP from TTP. Considering the technical parameters and feasibility of each identified method, DSC-pMRI was found to be the most promising technique.

Fluorescence-guided resection of high-grade gliomas: A systematic review and meta-analysis

2014 ◽  
Vol 11 (4) ◽  
pp. 451-458 ◽  
Author(s):  
Xing Su ◽  
Qing-Feng Huang ◽  
Hong-Lin Chen ◽  
Jian Chen
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
High Grade ◽  
High Grade Gliomas

scholarly journals Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I)

2021 ◽  
Vol 11 (3) ◽  
pp. 386
Author(s):  
Alice Giotta Lucifero ◽  
Sabino Luzzi
Keyword(s):  
Monoclonal Antibodies ◽  
Natural Killer ◽  
Immune Escape ◽  
Meta Analysis ◽  
Treatment Options ◽  
High Grade Glioma ◽  
High Grade ◽  
Future Challenges ◽  
Genetic Landscape ◽  
High Grade Gliomas

The resilience of high-grade gliomas (HGGs) against conventional chemotherapies is due to their heterogeneous genetic landscape, adaptive phenotypic changes, and immune escape mechanisms. Innovative immunotherapies have been developed to counteract the immunosuppressive capability of gliomas. Nevertheless, further research is needed to assess the efficacy of the immuno-based approach. The aim of this study is to review the newest immunotherapeutic approaches for glioma, focusing on the drug types, mechanisms of action, clinical pieces of evidence, and future challenges. A PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis)-based literature search was performed on PubMed/Medline and ClinicalTrials.gov databases using the keywords “active/adoptive immunotherapy,” “monoclonal antibodies,” “vaccine,” and “engineered T cell.”, combined with “malignant brain tumor”, “high-grade glioma.” Only articles written in English published in the last 10 years were selected, filtered based on best relevance. Active immunotherapies include systemic temozolomide, monoclonal antibodies, and vaccines. In several preclinical and clinical trials, adoptive immunotherapies, including T, natural killer, and natural killer T engineered cells, have been shown to be potential treatment options for relapsing gliomas. Systemic temozolomide is considered the backbone for newly diagnosed HGGs. Bevacizumab and rindopepimut are promising second-line treatments. Adoptive immunotherapies have been proven for relapsing tumors, but further evidence is needed.

Sign in / Sign up

Export Citation Format

Share Document